Genetic markers of severe cutaneous adverse reactions

키워드

참고문헌 (65)

1. Eichelbaum M, "Pharmacogenomics and individualized drug therapy", Annu Rev Med, 57, pp.119~137 (2006)[DOI]
2. Lazarou J, "Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies", JAMA, 279, pp.1200~1205 (1998)[DOI]
3. Roujeau JC, "Clinical heterogeneity of drug hypersensitivity", Toxicology, 209, pp.123~129 (2005)[DOI]
4. Mockenhaupt M, "Epidemiology of drug-induced severe skin reactions", Semin Cutan Med Surg, 15, pp.236~243 (1996)[DOI]
5. Strom BL, "A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures", Arch Dermatol, 127, pp.831~838 (1991)[DOI]
6. Mockenhaupt M, "The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis", Expert Rev Clin Immunol, 7, pp.803~813 (2011)[DOI]
7. Harr T, "Toxic epidermal necrolysis and Stevens-Johnson syndrome", Orphanet J Rare Dis, 5, pp.39~ (2010)[DOI]
8. Roujeau JC, "Immune mechanisms in drug allergy", Allergol Int, 55, pp.27~33 (2006)[DOI]
9. Roujeau JC, "Genetic susceptibility to toxic epidermal necrolysis", Arch Dermatol, 123, pp.1171~1173 (1987)[DOI]
10. Chung WH, "Human leukocyte antigens and drug hypersensitivity", Curr Opin Allergy Clin Immunol, 7, pp.317~323 (2007)[DOI]
11. Ko TM, "Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome", J Allergy Clin Immunol, 128, pp.1266~1276 (2011)[DOI]
12. Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir", N Engl J Med, 358, pp.568~579 (2008)[DOI]
13. Hetherington S, "Genetic variations in HLA-B region and hypersensitivity reactions to abacavir", Lancet, 359, pp.1121~1122 (2002)[DOI]
14. Mallal S, "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir", Lancet, 359, pp.727~732 (2002)[DOI]
15. Hughes AR, "Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations", Pharmacogenomics, 5, pp.203~211 (2004)[DOI]
16. Saag M, "High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients", Clin Infect Dis, 46, pp.1111~1118 (2008)[DOI]
17. Lee KW, "Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population", Tissue Antigens, 65, pp.437~447 (2005)[DOI]
18. Park HJ, "Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: a multicentre retrospective cohort study", Eur Radiol, 27, pp.2886~2893 (2017)[DOI]
19. Park WB, "Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?", Clin Infect Dis, 48, pp.365~367 (2009)[DOI]
20. Gatanaga H, "Pharmacogenetic information derived from analysis of HLA alleles", Pharmacogenomics, 9, pp.207~214 (2008)[DOI]
21. Phillips EJ, "Drug hypersensitivity: pharmacogenetics and clinical syndromes", J Allergy Clin Immunol, 127(3 Suppl), pp.S60~S66 (2011)[DOI]
22. Chantarangsu S, "HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients", Pharmacogenet Genomics, 19, pp.139~146 (2009)[DOI]
23. Martin AM, "Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts", AIDS, 19, pp.97~99 (2005)[DOI]
24. Gatanaga H, "HLA-Cw8 primarily associated with hypersensitivity to nevirapine", AIDS, 21, pp.264~265 (2007)[DOI]
25. Chung WH, "Medical genetics: a marker for Stevens-Johnson syndrome", Nature, 428, pp.486~ (2004)[DOI]
26. Chen P, "Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan", N Engl J Med, 364, pp.1126~1133 (2011)[DOI]
27. Dong D, "Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore", Neurology, 79, pp.1259~1267 (2012)[DOI]
28. Kuehn BM, "FDA: epilepsy drugs may carry skin risks for Asians", JAMA, 300, pp.2845~ (2008)[DOI]
29. Ferrell PB Jr, "Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations", Pharmacogenomics, 9, pp.1543~1546 (2008)[DOI]
30. Lonjou C, "A marker for Stevens-Johnson syndrome ...: ethnicity matters", Pharmacogenomics J, 6, pp.265~268 (2006)[DOI]
31. Kaniwa N, "HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis", Pharmacogenomics, 9, pp.1617~1622 (2008)[DOI]
32. Devi K, "The association of HLA B*15:02 allele and Stevens-Johnson syndrome", toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population, 2018, pp.57, 70~73
33. Man CB, "Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese", Epilepsia, 48, pp.1015~1018 (2007)[DOI]
34. Tassaneeyakul W, "Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population", Epilepsia, 51, pp.926~930 (2010)[DOI]
35. Then SM, "Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients", Asian Pac J Allergy Immunol, 29, pp.290~293 (2011)
36. Yip VL, "HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review", Clin Pharmacol Ther, 92, pp.757~765 (2012)[DOI]
37. Ozeki T, "Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population", Hum Mol Genet, 20, pp.1034~1041 (2011)[DOI]
38. McCormack M, "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans", N Engl J Med, 364, pp.1134~1143 (2011)[DOI]
39. Khor AH, "HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population", Pharmacogenet Genomics, 27, pp.275~278 (2017)[DOI]
40. Kim SH, "Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans", Epilepsy Res, 97, pp.190~197 (2011)[DOI]
41. Hung SI, "Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese", Pharmacogenomics, 11, pp.349~356 (2010)[DOI]
42. Ramirez E, "Significant HLA class I type associations with aromatic antiepileptic drug (AED)- induced SJS", TEN are different from those found for the same AED-induced DRESS in the Spanish population, 2017, pp.115, 168~178
43. Kazeem GR, "High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients", Pharmacogenet Genomics, 19, pp.661~665 (2009)[DOI]
44. Kim BK, "HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population", Ann Allergy Asthma Immunol, 118, pp.629~630 (2017)[DOI]
45. Koomdee N, "Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population", Front Pharmacol, 8, pp.879~ (2017)[DOI]
46. Moon J, "The HLA-A*2402", Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population, 2015, pp.56, e161~e167
47. Hung SI, "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol", Proc Natl Acad Sci U S A, 102, pp.4134~4139 (2005)[DOI]
48. Tassaneeyakul W, "Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population", Pharmacogenet Genomics, 19, pp.704~709 (2009)[DOI]
49. Kang HR, "Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans", Pharmacogenet Genomics, 21, pp.303~307 (2011)[DOI]
50. Lonjou C, "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs", Pharmacogenet Genomics, 18, pp.99~107 (2008)[DOI]
51. Goncalo M, "HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome", toxic epidermal necrolysis in a Portuguese population, 2013, pp.169, 660~665
52. Jung JW, "HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency", Nephrol Dial Transplant, 26, pp.3567~3572 (2011)[DOI]
53. Jung JW, "An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing", Genet Med, 17, pp.807~814 (2015)[DOI]
54. Ko TM, "Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study", BMJ, 351, pp.h4848~ (2015)
55. Shirato S, "Stevens-Johnson syndrome induced by methazolamide treatment", Arch Ophthalmol, 115, pp.550~553 (1997)[DOI]
56. Kim SH, "HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome", toxic epidermal necrolysis, 2010, pp.11, 879~884
57. Jee YK, "CD8(+) T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis", Clin Exp Allergy, 47, pp.972~974 (2017)[DOI]
58. Yang F, "HLA-B*59:01: a marker for Stevens-Johnson syndrome", toxic epidermal necrolysis caused by methazolamide in Han Chinese, 2016, pp.16, 83~87
59. Jiang YY, "Methazolamide-induced toxic epidermal necrolysis in a man carrying HLA-B*59:01: successful treatment with infliximab and glucocorticoid", Int J Dermatol, 57, pp.494~496 (2018)[DOI]
60. Shu C, "Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01", Int J Dermatol, 54, pp.1242~1245 (2015)[DOI]
61. Her Y, "Stevens-Johnson syndrome induced by acetazolamide", J Dermatol, 38, pp.272~275 (2011)[DOI]
62. Lorenz M, "Hypersensitivity reactions to dapsone: a systematic review", Acta Derm Venereol, 92, pp.194~199 (2012)[DOI]
63. Zhang FR, "HLA-B*13:01 and the dapsone hypersensitivity syndrome", N Engl J Med, 369, pp.1620~1628 (2013)[DOI]
64. Caudle KE, "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing", Clin Pharmacol Ther, 96, pp.542~548 (2014)[DOI]
65. Ciccacci C, "Association between CYP2B6 polymorphisms and Nevirapine-induced SJS", TEN: a pharmacogenetics study, 2013, pp.69, 1909~1916

관련 논문AI추천